All In Biotech

Drug Trial Radar · NCT07520045

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

A Comparative Analysis of OCT and OCT Angiography Biomarkers and Systemic Laboratory Parameters in Patients With Diabetic Retinopathy Undergoing Treatment With Faricimab or Biosimilar Ranibizumab Following Three Loading Doses

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 12, 2026

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Osijek University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are: Which OCT and OCT angiography biomarkers predict early treatment response? How do imaging biomarkers change after three loading doses of treatment? Are imaging biomarkers associated with systemic laboratory parameters? Researchers will compare faricimab to biosimilar ranibizumab to see if there are differences in imaging biomarkers and early treatment response. Participants will: * be randomized in a 1:1 ratio using a computer-generated randomization sequence * undergo comprehensive ophthalmic examinations, including visual acuity and intraocular pressure measurement * undergo OCT and OCT angiography imaging at each visit * receive three intravitreal injections during the loading phase * attend follow-up visits from baseline to 4-5 weeks after the third injection * provide blood samples for systemic laboratory analysis

Conditions

  • Diabetic Retinopathy (DR)
  • Diabetic Macular Edema (DME)

Interventions

  • FaricimabDrug

    Faricimab will be administered via intravitreal injection.

  • Biosimilar ranibizumabDrug

    Biosimilar ranibizumab will be administered via intravitreal injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of OCT and OCTA biomarkers associated with early anatomical treatment response to faricimab and biosimilar ranibizumabTime frame: From enrollment to 4-5 weeks after the third intravitreal injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Osijek

    Osijek, Croatia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.